

## DISCUSSION

In the present study, the overall estimated survival time from at CD4+ lymphocyte count  $200 \times 10^6/L$  at  $200 \times 10^6/L$  to death was 43.4 months, which was (a little Ed-high light: give some statistical or quantifiable comparison) longer than that of from San Francisco Homosexual Cohort Study (SFHCS) (3), as the later observed a The median survival time of 38 months from CD4+ lymphocyte count at  $200 \times 10^6/L$  to death in San Francisco Homosexual Cohort Study was quite similar to the result months under similar experimental conditions. Additionally, the data obtained from SFHCS was similar to a Korean study which followed from the study of 17 Korean homosexual men men with a survival time of (39.7 months from their CD4+ lymphocyte count)  $200 \times 10^6/L$  (REF). Furthermore, in a multicenter AIDS cohort study, when the CD4+ lymphocytes were in the range of  $101-200 \times 10^6/L$ , at least 71% survival was observed in a 2.5 years period In Multicenter AIDS Cohort Study, 71 % of HIV infected persons with CD4+ lymphocyte count in the range of  $101-200 \times 10^6/L$  were alive for 2.5 years from 1989 to 1993 (4). Also, the above study indicated In this study the survival of 70.6 % of subjects survived for 2 years and 66.6 % of subjects survived for 2.5 years from the date of CD4+ lymphocyte count at the CD4+ lymphocyte count of  $200 \times 10^6/L$ . Interestingly, to death. The median survival time of 19.8 months from the estimated date of at CD4+ lymphocyte count at  $50 \times 10^6/L$  to death was observed in the present study was somewhat longer than that reported by Elizabeth GG (16 months)  $\rightarrow$  25% at 2 years (12) and Robert Yarchoan R showed that the median survival time of HIV infected persons with CD4+ lymphocyte count less than  $50 \times 10^6/L$  was (12.1 months) (95% confidence interval: 7.2-19.4 months) (13).

According to the previous report As suggested earlier, the that AIDS-defining diseases could be unequivocally diagnosed occurred at when CD4+ lymphocyte counts are of  $50 \times 10^6/L$  for diagnoses (REF), hence, we compared our results of survival time from at CD4+ lymphocyte count at  $50 \times 10^6/L$  to death with other AIDS survival studies. An investigation from France showed survival of 97% for 6 months and 86% of them for 12 months (14). However, Ninety seven percentages of AIDS patients survived at 6 months and 86% of them at 12 months in France (14) as depicted in Table 6. The median survival time of 16.4 months among in homosexual men of MACS shown in table 6 were shorter than the median survival time of were less than that of 19.8 months from the date of CD4+ lymphocyte count at  $50 \times 10^6/L$  where the survival of 19.8 months was noted to death in this study. Ed-Highlight: Not very clear. Our result was included in the range of median survival time data on the survival (from 8 months through to 28 months) were in accordance with many other by the studies on AIDS survival time of many countries across the globe (Table 6) (15-28).

Our results on the differential median survival time (23.6 months) between the median survival time from the date of CD4+ lymphocyte count at  $200 \times 10^6/L$  to death and that from and  $50 \times 10^6/L$   $50 \times 10^6/L$  to death was about 2 years (23.6 months). Our result was were in line with earlier reports supported by the reports that the time from HIV infection to CD4+

Formatted: Highlight

Formatted: Highlight

Formatted: Not Highlight

lymphocyte counts suggesting when the CD4+ lymphocytes are less than  $200 \times 10^6/L$ , an average of ~~is on average nearly two years or less than to manifest~~ ~~ation of AIDS defining~~ **OI** **Ed-Highlight: Define OI here** (3, 29).-

Formatted: Highlight

Formatted: Highlight

As ~~mentioned before~~ stated above, only 252 (31.1%) of 811 HIV positive infected Koreans were infected from foreigner abroad contracted the disease from non-Koreans outside of Korea. The statistical analysis of survival ~~time from~~ CD4+ lymphocyte counts ~~at~~  $200 \times 10^6/L$  or  $50 \times 10^6/L$  ~~to death based on the geography of depending on the place of infection indicated~~ showed a significant difference (Figure 1). Moreover, ~~hAs~~ hazard ratios from CD4+ lymphocyte count ~~at~~  $200 \times 10^6/L$  and  $50 \times 10^6/L$  ~~in among~~ subjects infected ~~abroad outside of Korea~~ were 2.84 ( $p=0.0398$ ) and 2.40 ( $p=0.0444$ ) ~~respectively, which was significant different by with a confidence interval of 95% confidence interval. This data showed that suggesting the~~ subjects infected inside Korea survived longer ~~than those infected abroad.~~

Supporting our present data, ~~According to the~~ molecular epidemiological study of HIV subtypes in Korea (6) found that, the predominance of Subtype B and distinct subclusters with in subtype B in patients infected in Korea. On the contrary the subtype of HIV-1 from whom infected inside Korea was not only subtype B but also the strains grouped into distinct subcluster within subtype B which was different with those from North America and Europe. However, the subtypes of HIV-1 from whom infected abroad the infections outside of Korea identified various subtypes including ~~subtypes~~ A, E, B, C, D, G and ~~subtypes~~ H. As suggested by Kanki et al. suggested that HIV-1 subtypes may determine the rates of progression to AIDS (30) ~~), and hence it will be of interest to study whether HIV-1 subtype B found be predominant in Korea may affect the survival and may also be related to the prognosis or not of the disease. Based on those results, we need~~ The above observations ~~strengthen the need for investigations studies to identify the factors which may positively influence the survival after at CD4+ lymphocyte count at~~  $200 \times 10^6/L$  or  $50 \times 10^6/L$ . **Furthermore, We also need further study which shed light on on whether the infection was acquires in Korea or abroad geography of the infection as an important factor to determine and disease is progression and an important factor to determine overall survival time from seroconversion to death or not.** **ED-Highlight: This sentence is redundant here as it appears in the last paragraph of the conclusion.**

Formatted: Highlight

Formatted: Highlight

The rate of ~~loss of~~ CD4+ cells ~~loss~~ was significantly associated with survival time ~~at from~~ CD4+ lymphocyte counts ~~at~~  $200 \times 10^6/L$  or  $50 \times 10^6/L$  ~~to death. Since, (Because the loss of CD4+ cells means the leads to dysfunction of immune system, it is understood, there exists a direct correlation of number of CD4+ cells and survival time. we could understand that subjects with the higher rate of CD4+ cell loss survived shorter than other groups.~~

The effective CD8+ cell-mediated immune response has been closely linked to a beneficial host response to infection with retrovirus. Recent studies have suggested that the CD8+ T cell is an important lymphocyte subset in the pathogenesis of HIV infection and is correlated with disease outcome (2-4). ~~Indeed, aA~~ strong HIV-specific immune response can prevent the ~~disease progression quantitatively and qualitatively. immune defects of disease progression by HIV-~~

Formatted: Not Superscript/ Subscript

~~infection~~. CD8+ T cells ~~can~~ are shown to suppress HIV replication in peripheral blood mononuclear cells (PBMCs) (REF). The antiviral effect of CD8+ T cells is mediated by HIV suppressor factors secreted from CD8+ T cells such as stromal cell-~~drived~~derived factors (SDF-1), eotaxin, monocyte chemotactic proteins (MCP-1), macrophage-derived chemokine (MDC), CD8+ cell antiviral factor (CAF), and interleukin 16 (IL-16) ~~et al~~ among others (REF). Recent studies also suggested that beta-chemokines (RANTES, MIP-1~~α~~α and MIP-1~~β~~β) produced by CD8+ T cells ~~showed~~ exhibited a synergistic effect leading to the suppression of HIV replication *in vitro* (REF). CD8+ T cells with anti-HIV activity, especially CTLs, limit the disease progression after HIV infection~~decreases as an HIV infected person progresses from a healthy state to an AIDS condition~~. ~~Thus~~ therefore, the ~~high rate~~ higher loss of CD8+ cells ~~loss~~ inversely affected the survival ~~at~~ from CD4+ lymphocyte count ~~at~~ 200 × 10<sup>6</sup>/L, ~~however~~, ~~But~~ the rate of the exact ~~role of~~ CD8+ was not evident on survival, ~~cell loss~~ did not affect the survival from ~~after~~ CD4+ lymphocyte counts reached ~~at~~ 50 × 10<sup>6</sup>/L. Further studies are warranted to underscore the insights of CD8+ cells at We need to study the characterization of CD8+ T cells in detail to explain our result that the rate CD8+ cell loss was lower affect in survival from CD4+ lymphocyte count at 50 × 10<sup>6</sup>/L than at 200 × 10<sup>6</sup>/L.

Formatted: Highlight

Formatted: Highlight

Formatted: Font: Not Italic, Highlight

Gender, age, route of infection ~~route~~ and AZT treatment did not ~~affected~~ statistically affect the ~~on the~~ survival time ~~at~~ from CD4+ lymphocyte count ~~at~~ 200 × 10<sup>6</sup>/L or ~~50 × 10<sup>6</sup>/L~~ to death.

Age was identified as a cofactor of HIV progression, and the effect of age was subsequently confirmed in many studies (31, 32). Interestingly, at the CD4+ lymphocyte count 200 × 10<sup>6</sup>/L, ~~the~~ the median survival time was shorter in subjects older than 34 years compared to their young counterparts from CD4+ lymphocyte count at 200 × 10<sup>6</sup>/L, to death was slightly shorter among group over age 34 than under age 34. Similarly, the Hazard ratio of subjects older than 34 years for over age 34 was found to be 0.82 (p=0.6332) on survival after at CD4+ lymphocyte count at 200 × 10<sup>6</sup>/L and that for over age subjects older than 38, was 1.12 (p=0.7560) on survival after at CD4+ lymphocyte count at 50 × 10<sup>6</sup>/L, after adjustment for other factors. ~~However, we could not find a statistically significant difference by age in our study. The interpretation of these results was that age did not affect on survival time from CD4+ lymphocyte count at 200 × 10<sup>6</sup>/L or 50 × 10<sup>6</sup>/L to death. Though the differences of age between younger and older groups was about 10 years, survival difference between the older and younger groups were approximately 10 years, the data did not yield statistically significant difference. It is noteworthy to mention here that~~ —

Longer survival time and lower hazard ratio from at CD4+ lymphocyte count at 200 × 10<sup>6</sup>/L or 50 × 10<sup>6</sup>/L were demonstrated among subjects infected through transfusion or blood product than those infected by sexual contacts by Ed-Highlight: is this from the current study or from a literature?

Formatted: Normal

Formatted: Highlight

Our univariate estimate showing longer survival among subjects infected through transfusion ~~or blood product~~ was ~~ere~~ different from other studies in which survival trends of hemophiliacs were similar to those of homosexual men and intravenous drugs users ~~with AIDS~~ (17, 33, 34). ~~But~~

However, the route of infection route did not significantly affect significantly on survival from the survival at the CD4+ lymphocyte counts at  $200 \times 10^6/L$  or  $50 \times 10^6/L$  to death since the possibility due to the low power of the study, number of subjects through transfusion or blood product was small.

After AZT was licensed, As AZT has come into use, number of reports indicated that treatment of AZT increased the survival by at least 10 months in AIDS patients. Many studies was reported that AIDS cases treated with AZT had a median survival of more than 20 months, compared with about 10 months for AIDS cases not treated (35-38), however. But some studies reported that literature also argue that early initiation of antiretroviral therapy might have little effect on overall survival time (39, 40). Our results showed suggest that AZT treatment did not affect the median survival after at the CD4+ lymphocyte counts at  $200 \times 10^6/L$  or  $50 \times 10^6/L$ , which was. However contrary to some reports which showed, some studies suggested that AZT treatment could affected the rate of CD4+ cell loss (41, 42) and increase survival time. One explanation to this conundrum could be It is the possible extension of that AIDS incubation period was extended because the rate of CD4+ cell loss was lower before AIDS onset low rate of CD4+ cell loss at the onset stage.s. Since 1997 in Korea, the In Korea, since 1997, there has been a rapid increase in the use of combination antiretroviral therapy including protease inhibitors in HIV positive individuals. Many studies. percentage of HIV infected persons who receive the combination therapy including protease inhibitor has increased rapidly. It has been reported that the support that the combination therapy had a significant effect on lengthening survival time significantly improved survival time in HIV patients (43, 44), but however, it is still uncertain is the extent of effect of combination this therapy on survival in these patients ED-Highlight. Not very clear of this sentence!! is still uncertain. Although AZT treatment did not show any positive effect on survival after at the CD4+ lymphocyte counts at  $200 \times 10^6/L$  or  $50 \times 10^6/L$ , we need a longitudinal study may be necessary unravel to investigate the effects of the combination therapy, apart from including the AZT mono therapy, on survival among in HIV infected persons positive individuals. —

The present investigation is the This study is the first to report on the the survival time and survival rate from HIV positive individuals of Korean origin. AIDS indicated level to death in Korean. The median survival time after AIDS indicated level is similar with results of corroborating to the data obtained in studies across the globe in other countries. Though, While we had the limitation that low power as well. the number of subjects enrolled included in survival study are the limitations of the present manuscript, dy was small, we found interesting characteristic that an interesting finding in our study is that. individuals who contracted the disease HIV infection inside Korea had significantly longer survival time from at the CD4+ lymphocyte counts at  $200 \times 10^6/L$  or  $50 \times 10^6/L$  to death. Further studies are warranted We need further to study identify which the factors influence affect the natural history of HIV infection from seroconversion to death.

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight